Dermatol. praxi. 2024;18(1):19-23 | DOI: 10.36290/der.2024.004

Drug hypersensitivity reactions

MUDr. Mojmír Račanský
Oddělení alergologie a klinické imunologie, Fakultní nemocnice Olomouc

Drug hypersensitivity reactions are a healthcare problem with rising incidence. Adverse events diagnostic or therapeutical drugs could negatively affect patients' quality of life and increase healthcare costs. The first signs of drug hypersensitivity reactions involve skin or mucosal surfaces. Skin symptoms like acute urticaria or angioedemas and delayed reaction with maculopapular eruptions are well described. Those conditions could be the initial step to life-threatening reactions like anaphylaxis or severe cutaneous adverse reactions - Steven-Jones Syndrome, for example. This summary brings the current view on drug hypersensitivity symptoms, diagnostics and management.

Keywords: drug hypersensitivity reactions, skin.

Accepted: March 26, 2024; Published: April 3, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Račanský M. Drug hypersensitivity reactions. Dermatol. praxi. 2024;18(1):19-23. doi: 10.36290/der.2024.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy.
    2. Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy. 2019;74:1457. Go to original source... Go to PubMed...
    3. Pichler WJ, Adam J, Watkins S, et al. Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors. Int Arch Allergy Immunol. 2015;168:13. Go to original source... Go to PubMed...
    4. Pichler WJ, Thoo L, Yerly D. Drug hypersensitivity and eosinophilia: The decisive role of p-i stimulation. Allergy. 2023;78:2596. Go to original source... Go to PubMed...
    5. McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015;519:237. Go to original source... Go to PubMed...
    6. Yun J, Adam J, Yerly D, Pichler WJ. Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy. 2012;67(11):1338-1346. doi: 10.1111/all.12008. Epub 2012 Sep 3. PMID: 22943588. Go to original source... Go to PubMed...
    7. Muraro A, Worm M, Alviani C, et al. EAACI guidelines: Anaphylaxis (2021 update). Allergy. 2022;77(2):357-377. doi: 10.1111/all.15032. Epub 2021 Sep 1. PMID: 34343358. Go to original source... Go to PubMed...
    8. Frey N, Jossi J, Bodmer M, et al. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J Invest Dermatol. 2017;137:1240. Go to original source... Go to PubMed...
    9. Lee HY. Drug reaction with eosinophylia and systemic symptoms (DRESS) In: UpToDate, Mockenhaupt M (Ed), Wolters Kluwer.
    10. Gibson A, Deshpande P, Campbell CN, et al. Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. J Allergy Clin Immunol. 2023;151:289. Go to original source... Go to PubMed...
    11. Duong TA, Valeyrie-Allanore L, Wolkenstein P, et al. Severe cutaneous adversecreactions to drugs. Lancet. 2017;390:1996. Go to original source... Go to PubMed...
    12. Torres-Navarro I, Briz-Redón Á, Botella-Estrada R. Systemic therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN based systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35:159. Go to original source... Go to PubMed...
    13. Tsai TY, Huang IH, Chao YC, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis. J Am Acad Dermatol. 2021;84:390. Go to original source... Go to PubMed...
    14. Creadore A, Desai S, Alloo A, et al. Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US. JAMA Dermatol. 2022;158:176. Go to original source... Go to PubMed...
    15. Speeckaert MM, Speeckaert R, Lambert J, et al. Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur J Dermatol. 2010;20:425. Go to original source... Go to PubMed...
    16. Alniemi DT, Wetter DA, Bridges AG, et al. Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996-2013. Int J Dermatol. 2017;56:405. Go to original source... Go to PubMed...
    17. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071. Go to original source... Go to PubMed...
    18. Cabañas R, Ramírez E, Sendagorta E, et al. Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS Syndrome. J Investig Allergol Clin Immunol. 2020;30(4):229-253. doi: 10.18176/jiaci.0480. Epub 2020 Jan 14. PMID: 31932268. Go to original source... Go to PubMed...
    19. Nguyen E, Yanes D, Imadojemu S, et al. Evaluation of Cyclosporine for the Treatment of DRESS Syndrome. JAMA Dermatol. 2020;156:704. Go to original source... Go to PubMed...
    20. Singer EM, Wanat KA, Rosenbach MA. A case of recalcitrant DRESS syndrome with multiple autoimmune sequelae treated with intravenous immunoglobulins. JAMA Dermatol. 2013;149:494. Go to original source... Go to PubMed...
    21. Damsky WE, Vesely MD, Lee AI, et al. Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. JAAD Case Rep. 2019;5:1018. Go to original source... Go to PubMed...
    22. Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: A 2022 practice parameter update. J Allergy Clin Immunol. 2022 Dec;150(6):1333-1393. doi: 10.1016/j.jaci.2022.08.028. Epub 2022 Sep 17. PMID: 36122788. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.